# David Benshoof Klein

> David Benshoof Klein is the New York-based co-founder and CEO of Click Therapeutics, which he founded in 2012. A former managing director at Opus Point Partners and senior consultant to Pfizer, he has also served as guest faculty at Columbia and NYU and co-founded Eli Klein Gallery. His public writing connects workplace equality with the influence of his mother, human rights lawyer Janet Benshoof.

- **Role:** Co-founder and CEO at Click Therapeutics, Inc.
- **Organizations:** Click Therapeutics, Inc., Eli Klein Gallery, Opus Point Partners (former), Pfizer (former consultant), Columbia University (guest faculty), New York University Stern School of Business (guest faculty), Columbia Business School (guest faculty)
- **Education:** Bachelor’s degree (B.A.), Brandeis University
- **Known for:** Co-founded Click Therapeutics in 2012 and remains its CEO., Co-founded Eli Klein Gallery., Selected by Goldman Sachs among its 100 Most Intriguing Entrepreneurs of 2019.

## Career timeline

- **1996-2001** — Attended Brandeis University; holds a B.A.
- **Before 2012** — Served as managing director at Opus Point Partners.
- **2012** — Co-founded Click Therapeutics.
- **2019** — Recognized at Goldman Sachs’ Builders + Innovators Summit.
- **2021** — Click closed a $52 million Series B financing.
- **2024** — Named to the PharmaVoice 100 list; published an essay on his mother’s influence and workplace equality.
- **2025** — Dassault Systèmes and Medidata made a strategic investment in Click.
- **2026** — Boehringer Ingelheim made a $50 million Series D strategic investment in Click, alongside dedicated commercial funding.

## Achievements

- Co-founded Click Therapeutics in 2012 and remains its CEO.
- Co-founded Eli Klein Gallery.
- Selected by Goldman Sachs among its 100 Most Intriguing Entrepreneurs of 2019.
- Named a 2024 PharmaVoice 100 honoree in the Tech and AI category.
- Has served as guest faculty at Columbia University, Columbia Business School, and NYU Stern.

## Latest updates

- **2026-04** — Click announced a $50 million Series D strategic investment by Boehringer Ingelheim and additional dedicated commercial funding.
- **2026-03** — In an Investment Reports interview, Klein discussed partnerships and said any IPO would ultimately be a board decision.
- **2026-01** — Click announced a collaboration with Ultrahuman.

## Links

- Website: https://www.clicktherapeutics.com/team/david-b-klein
- LinkedIn: https://www.linkedin.com/in/davidbklein

---

Profile page: https://yespress.io/david-benshoof-klein
Published by YesPress — https://yespress.io
Last updated: 2026-10-25